As of December 31, 2025, unrestricted cash and cash equivalents and marketable debt securities totaled $197.9 million, including proceeds from the Company’s $86.3 million public offering in December 2025. The Company expects its cash and cash equivalents and marketable debt securities will be sufficient to fund its planned operations and milestones into 2028.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- TARA Upcoming Earnings Report: What to Expect?
- De-Risked Lead Asset and Underappreciated Pipeline Upside Support Buy Rating on Protara
- Protara Therapeutics initiated with an Overweight at JPMorgan
- Protara Highlights Strong Phase 2 Data for TARA-002
- Reframing TARA‑002’s Potential: Underappreciated Durability and Commercial Upside in BCG‑Unresponsive NMIBC